Richard Penson

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Laughter: the best medicine?
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, 02114 2617, USA
    Oncologist 10:651-60. 2005
  2. ncbi request reprint Between parent and child: negotiating cancer treatment in adolescents
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 7:154-62. 2002
  3. ncbi request reprint Fear of death
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Palliative Care Service, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 10:160-9. 2005
  4. ncbi request reprint Topotecan: weighing in when there are many options
    Richard T Penson
    Department of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 10:698-700. 2005
  5. ncbi request reprint A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors
    R T Penson
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Int J Gynecol Cancer 15:1035-41. 2005
  6. doi request reprint Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
    Richard T Penson
    MRCP, Division of Hematology Oncology, Yawkey 9 064, Massachusetts General Hospital, 32 Fruit St, Boston MA 02114, USA
    J Clin Oncol 28:154-9. 2010
  7. ncbi request reprint The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114 2617, USA
    Oncologist 8:488-95. 2003
  8. ncbi request reprint Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies
    Richard T Penson
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 93:702-7. 2004
  9. ncbi request reprint Help me help you: support groups in cancer therapy
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 9:217-25. 2004
  10. ncbi request reprint Too old to care?
    Richard T Penson
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 9:343-52. 2004

Detail Information

Publications64

  1. ncbi request reprint Laughter: the best medicine?
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, 02114 2617, USA
    Oncologist 10:651-60. 2005
    ..Through an examination of physician and nurse experiences, the role of humor in medicine is reviewed...
  2. ncbi request reprint Between parent and child: negotiating cancer treatment in adolescents
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 7:154-62. 2002
    ..The epidemiology of cancer in adolescents and paradigms of care are reviewed. Psychosocial aspects of adolescence, opportunities for personal growth and support, and the challenge of end-of-life care are discussed...
  3. ncbi request reprint Fear of death
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Palliative Care Service, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 10:160-9. 2005
    ..Through an examination of eight caregiver narratives of their patients' experiences, the role of the health care provider in the dying process, particularly in regard to challenging fear, is reviewed...
  4. ncbi request reprint Topotecan: weighing in when there are many options
    Richard T Penson
    Department of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 10:698-700. 2005
    ....
  5. ncbi request reprint A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors
    R T Penson
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Int J Gynecol Cancer 15:1035-41. 2005
    ..The optimal dose and schedule of gemcitabine is yet to be defined in this population...
  6. doi request reprint Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
    Richard T Penson
    MRCP, Division of Hematology Oncology, Yawkey 9 064, Massachusetts General Hospital, 32 Fruit St, Boston MA 02114, USA
    J Clin Oncol 28:154-9. 2010
    ..The progression-free survival rate at 36 months was 58%. CONCLUSION The regimen of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab is feasible, safe, and worthy of future study in advanced ovarian cancer...
  7. ncbi request reprint The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114 2617, USA
    Oncologist 8:488-95. 2003
    ..The team developed a strong commitment to his care and an affectionate bond, which very positively affected all of those involved. We discuss issues of access to cancer care, and the special problems presented by homeless patients...
  8. ncbi request reprint Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies
    Richard T Penson
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 93:702-7. 2004
    ..Topotecan and pegylated liposomal doxorubicin (Doxil) interact with topoisomerase I and II (topo I and II), respectively, with schedule dependent, and potentially synergistic cytotoxicity...
  9. ncbi request reprint Help me help you: support groups in cancer therapy
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 9:217-25. 2004
    ..The article discusses issues of support and the role of formal support groups. Types of support intervention, the impact they have on quality of life and survival are reviewed...
  10. ncbi request reprint Too old to care?
    Richard T Penson
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 9:343-52. 2004
    ..Discussion in the Rounds focused on age bias, drug toxicity, life prolongation, and symptom relief, with the role of the caregiver, and the relationship to the patient, being pivotal...
  11. ncbi request reprint Attitudes to chemotherapy in patients with ovarian cancer
    R T Penson
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 94:427-35. 2004
    ..Recurrent ovarian cancer (OVCA) has become the model for cancer as a chronic disease, yet little is known about what motivates patients and physicians in treatment choices...
  12. ncbi request reprint Cancer as metaphor
    Richard T Penson
    Department of Medicine, Hematology Oncology, Cox 548, 100 Blossom Street, Boston, Massachusetts 02114 2617, USA
    Oncologist 9:708-16. 2004
    ..The advantages and disadvantages of the use of this metaphor are discussed, as well as the use of other metaphors in the psychosocial dynamic of care...
  13. ncbi request reprint Hope
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Yawkey 9066, 55 Fruit Street, Boston, Massachusetts 02114 2617, USA
    Oncologist 12:1105-13. 2007
    ..The literature and limited evidence base are reviewed...
  14. doi request reprint Bevacizumab and ovarian cancer
    G G Y Lai
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Drugs Today (Barc) 47:669-81. 2011
    ....
  15. pmc A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
    R T Penson
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Br J Cancer 93:54-9. 2005
    ..Oral etoposide 35 mg m(-2) b.i.d. D1-5 and 1.8 mg m(-2) 96 h (total dose) infusional topotecan D8-11 can be administered on an alternating continual weekly schedule for at least 12 weeks, with promising clinical activity...
  16. ncbi request reprint Quality of life in ovarian cancer
    Richard Penson
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Reprod Med 50:407-16. 2005
    ..While the humanities perhaps teach us much about the value of QOL, the science of the study of QOL will be the foundation and confirmation of many of the anticipated advances for patients...
  17. ncbi request reprint Teams: communication in multidisciplinary care
    Richard T Penson
    The Kenneth B Schwartz Center at Massachusetts General Hospital, Department of Medicine, Boston, Massachusetts 02114 2617, USA
    Oncologist 11:520-6. 2006
    ..This article explores the tough issue of how teams handle uncertainty and bad news and how patients and families can be better supported in the multifaceted paradigm of modern care...
  18. ncbi request reprint Trust violated: analgesics for addicts
    Richard T Penson
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114 2617, USA
    Oncologist 8:199-209. 2003
    ..With open and honest support, the team was able to both care for and empower the patient. Issues of trust, liability, opioid tolerance, and barriers to optimal analgesia for cancer pain are discussed...
  19. ncbi request reprint Medical mistakes: a workshop on personal perspectives
    R T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 6:92-9. 2001
    ..Openly sharing experiences in a confidential setting, such as the Schwartz Rounds, helps defuse feelings of guilt and challenges the culture of shame and isolation that often surrounds medical errors. The Oncologist 2001;6:92-99..
  20. ncbi request reprint Randomized placebo-controlled trial of the activity of the morphine glucuronides
    R T Penson
    Department of Medical Oncology, St Bartholomew s Hospital, London, England
    Clin Pharmacol Ther 68:667-76. 2000
    ..It has been suggested from animal model data and by examination of metabolite ratios in humans that M3G may functionally antagonize the respiratory depressant and analgesic actions of morphine and M6G...
  21. ncbi request reprint Caring for colleagues
    R T Penson
    Department of Medicine, Division of Hematology Oncology, Cox 809, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114 2617, USA
    Oncologist 6:197-204. 2001
    ....
  22. ncbi request reprint Losing God
    R T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114 2617, USA
    Oncologist 6:286-97. 2001
    ..Simply being there for the patient and being open to their hurt can help resolve their spiritual crisis, a responsibility that is shared by the whole health care team...
  23. ncbi request reprint Complementary, alternative, integrative, or unconventional medicine?
    R T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 6:463-73. 2001
    ..Concern about drug interactions and adverse effects are compounded by a lack of Food and Drug Administration regulation. Physicians need to be informed about CAM and be attuned to the psychosocial needs of patients...
  24. ncbi request reprint Limited phase I study of morphine-3-glucuronide
    R T Penson
    Division of Hematology Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, Massachusetts 02114, USA
    J Pharm Sci 90:1810-6. 2001
    ..1 (+/- 4.8) liters. At the doses investigated there were no clear neuroexcitatory effects, no opioid effects, and the pharmacokinetics were very similar to those of morphine-6-glucuronide (M6G)...
  25. ncbi request reprint Sexuality and cancer: conversation comfort zone
    R T Penson
    The Kenneth B Schwartz Center at Massachusetts General Hospital, Hematology Oncology Department, Boston, Massachusettts 02114 2617, USA
    Oncologist 5:336-44. 2000
    ..A sensitive and informed approach to discussing sexuality can provide effective support. The elements of successful dialogue are presented in the PLISSIT model...
  26. ncbi request reprint Communicating genetic risk: pros, cons, and counsel
    R T Penson
    Hematology Oncology Department, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 5:152-61. 2000
    ....
  27. ncbi request reprint Burnout: caring for the caregivers
    R T Penson
    The Kenneth B Schwartz Center at Massachusetts General Hospital, Hematology Oncology Department, Boston, Massachusetts, USA
    Oncologist 5:425-34. 2000
    ..They considered preventative measures including psychological support of the health care team, communication and management skills, and effective coping mechanisms...
  28. ncbi request reprint Virtual connections: Internet health care
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Cox 548, 100 Blossom Street, Boston, MA 02114 2617, USA
    Oncologist 7:555-68. 2002
    ....
  29. pmc Connection: Schwartz Center Rounds at Massachusetts General Hospital Cancer Center
    Richard T Penson
    M R C P, Hematology Oncology, Yawkey 9064, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Oncologist 15:760-4. 2010
    ..In this article we explore the reasons that contribute to the success of this model of multidisciplinary reflection...
  30. ncbi request reprint When does the responsibility of our care end: bereavement
    Richard T Penson
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 7:251-8. 2002
    ..A compassionate response helps both those who suffer and those who care. Complicated and uncomplicated bereavement, grief reactions, resources for bereavement counseling, and the role of condolence letters are reviewed...
  31. ncbi request reprint Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer
    Ursula A Matulonis
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Pain Symptom Manage 30:563-9. 2005
    ..No significant toxicities were attributable to octreotide or LAR. Because three patients received nine or more monthly injections of LAR, possible direct antitumor effects of LAR or synergy with chemotherapy needs to be explored...
  32. ncbi request reprint Living as a cancer surpriser: a doctor tells his story
    Kristine A Knuti
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 8:108-22. 2003
    ..In addition to such processes, patient-caregivers with cancer also find that their own medical knowledge and their colleagues' reactions shape their experiences and to an extent separate them from those of other patients...
  33. ncbi request reprint Phase II trial of anastrozole in women with asymptomatic müllerian cancer
    Marcela G del Carmen
    Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 91:596-602. 2003
    ..To evaluate the efficacy and toxicity of the selective aromatase inhibitor anastrozole (Arimidex), we conducted a phase II trial in 53 women with asymptomatic recurrent/persistent müllerian cancer...
  34. ncbi request reprint Direct-to-consumer advertising in oncology
    Gregory A Abel
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114 2617, USA
    Oncologist 11:217-26. 2006
    ..Although sparse, the medical literature on this increasingly prevalent type of medical communication is also reviewed...
  35. doi request reprint Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors
    Ursula A Matulonis
    Department of Medical Oncology Dana Farber Cancer Institute, Boston, MA 02115, USA
    Gynecol Oncol 112:394-9. 2009
    ..The primary objective was to determine the completion rate of 6 cycles of paclitaxel and carboplatin chemotherapy with no dose reductions in patients > or =70 years of age...
  36. ncbi request reprint Learning to cope: how far is too close?
    Brian M Wolpin
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 10:449-56. 2005
    ..To conclude, further educational initiatives are advocated to assist both physicians-in-training and more senior clinicians in dealing with the difficult issues that arise when caring for very ill and dying patients...
  37. pmc Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
    J Clin Oncol 27:5601-6. 2009
    ..Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit...
  38. ncbi request reprint Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary
    Linda R Duska
    Vincent Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Gynecol Oncol 85:459-63. 2002
    ..The current study was undertaken to characterize a group of patients treated as if they had aggressive epithelial ovarian tumors, with cytoreductive surgery and combination paclitaxel/platinum chemotherapy...
  39. doi request reprint Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston MA 02115, USA
    J Clin Oncol 26:5761-6. 2008
    ..Pemetrexed is a multitargeted antifolate with manageable toxicity and has been combined with carboplatin to treat other cancers...
  40. ncbi request reprint Breaking bad news: a patient's perspective
    Lauren Dias
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 8:587-96. 2003
    ..This article discusses issues of support, abandonment, and how hope is conveyed, and reviews the literature that informs good clinical practice in breaking bad news...
  41. pmc Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor
    Emily S Robinson
    Channing Laboratory, 3rd Floor, 181 Longwood Avenue, Boston, MA 02115, USA
    Clin J Am Soc Nephrol 5:477-83. 2010
    ..In this phase II study of cediranib (AZD2171) for recurrent epithelial ovarian cancer, the time course and severity of BP changes and proteinuria were characterized...
  42. ncbi request reprint Psychosocial issues in adolescents with cancer
    Annah N Abrams
    Department of Child Psychiatry and Pediatric Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, United States
    Cancer Treat Rev 33:622-30. 2007
    ....
  43. doi request reprint Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management
    Paul E Hesterberg
    Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Allergy Clin Immunol 123:1262-7.e1. 2009
    ..Women with ovarian cancer treated with chemotherapeutic platinum agents frequently develop hypersensitivity reactions (HSRs). How best to risk-stratify patients for desensitization is uncertain...
  44. ncbi request reprint Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer
    Richard T Penson
    Harvard Medical School, Boston, MA, USA
    Int J Gynaecol Obstet 95:S247-57. 2006
    ..The QOL issues facing gynecologic cancer patients, the use of validated QOL instruments, recent advances in the evaluation of interventions, and changes in concepts related to QOL are reviewed...
  45. ncbi request reprint A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer
    Michael V Seiden
    Gynecologic Oncology Research Program at Dana Farber Partners Cancer Care Program, Boston, MA 02115, USA
    Gynecol Oncol 101:55-61. 2006
    ..To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy...
  46. doi request reprint Comparison of the quality of life of early and advanced stage ovarian cancer survivors
    Kristina L Mirabeau-Beale
    Harvard Medical School, Boston, MA, USA
    Gynecol Oncol 114:353-9. 2009
    ..The objective of this study was to compare the long-term adjustment and QOL of early and advanced stage ovarian cancer survivors (OCS)...
  47. ncbi request reprint Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors
    Susanna M Campos
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Gynecol Oncol 90:610-8. 2003
    ..Ortho-Biotech) and paclitaxel (Taxol, Bristol Myers Squibb) are both active against Müllerian malignancies. A phase II trial was performed to determine the toxicity and efficacy of these agents when administered in combination...
  48. ncbi request reprint beta tubulin mutations are rare in human ovarian carcinoma
    Diana E Lamendola
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Anticancer Res 23:681-6. 2003
    ..The interaction between paclitaxel and its target, beta tubulin, is essential for effective cytotoxicity. Alterations or mutation of beta tubulin have the potential to alter paclitaxel binding and confer a drug resistant phenotype...
  49. ncbi request reprint Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Stephen A Cannistra
    Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 25:5180-6. 2007
    ....
  50. doi request reprint Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients
    Elizabeth Dean-Clower
    Leonard P Zakim Center for Integrative Therapies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Integr Cancer Ther 9:158-67. 2010
    ..The main study objectives were to determine the feasibility of administering acupuncture as palliative therapy to patients with advanced ovarian or breast cancer and to assess the effect on symptoms and quality of life (QOL)...
  51. ncbi request reprint A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Anna Berkenblit
    Dana Farber Harvard Cancer Center Program in Gynecologic Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Gynecol Oncol 95:624-31. 2004
    ..To determine the activity and tolerability of weekly docetaxel in patients with platinum-resistant mullerian origin tumors...
  52. ncbi request reprint Morphine analgesia in cancer pain: role of the glucuronides
    Richard T Penson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Opioid Manag 1:83-90. 2005
    ..01) than morphine (r = 0.197, p = 0.05). These data suggest that M6G contributes significantly to the analgesic potency of oral morphine. No evidence was found for differences in M3G. M6G ratios contributing to analgesia or toxicity...
  53. doi request reprint Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors
    Maria R Roche
    Dana Farber Harvard Cancer Center, representing members of the DF HCC Gynecologic Oncology Research Group at Massachusetts General Hospital, and Dana Farber Cancer Institute, Boston, MA, USA
    Gynecol Oncol 116:168-72. 2010
    ..The primary objective was to define the median time to treatment termination (TTT) with women with relapsed ovarian cancer treated with single agent GM-CSF delivered subcutaneously (SC)...
  54. ncbi request reprint Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines
    Zhenfeng Duan
    Department of Hematology Oncology Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 9:2778-85. 2003
    ..These antigens, because of limited expression in normal tissues, may be suitable targets for immunotherapy and novel therapeutic strategies in the treatment of chemotherapy-resistant epithelial tumors...
  55. ncbi request reprint Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples
    Richard T Penson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 93:98-106. 2004
    ....
  56. pmc Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial
    Weidong Lu
    Leonard P Zakim Center for Integrative Therapies, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Altern Complement Med 15:745-53. 2009
    ..The objective of this study was to investigate the effect of acupuncture administered during myelosuppressive chemotherapy on white blood cell (WBC) count and absolute neutrophil count (ANC) in patients with ovarian cancer...
  57. pmc The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide
    Richard T Penson
    Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London, EC1A 7BE
    Br J Clin Pharmacol 53:347-54. 2002
    ..The aim of this study was to define the pharmacokinetics, toxicity and cardio-respiratory effects of three alternative routes of administration of M6G...
  58. doi request reprint Ovarian stromal and germ cell tumors
    Carolyn R Koulouris
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Semin Oncol 36:126-36. 2009
    ..Most patients with germ cell tumors require adjuvant chemotherapy with bleomycin, etoposide, and cisplatin (BEP), as well as careful surveillance. The rarity of these tumors makes basic scientific advances more challenging...
  59. ncbi request reprint Silence as the speech of care
    Corrina Lee
    Division of Hematology at Massachusetts General Hospital, Boston, USA
    J Support Oncol 2:455-6. 2004
  60. doi request reprint Epithelioid angiosarcoma of the uterus: a review of management
    Alexander B Olawaiye
    Gynecologic Oncology Division, Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Arch Gynecol Obstet 278:401-4. 2008
    ..Uterine epithelioid angiosarcoma is extremely rare. Evidence-based advice regarding optimal management is lacking...
  61. ncbi request reprint Faith, identity, and leukemia: when blood products are not an option
    Kristine A Knuti
    Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 7:371-80. 2002
    ..Jehovah's Witness beliefs regarding blood products are reviewed. Caregiver roles and responsibilities are discussed in the context of psychosocial, legal, familial, and ethical issues...
  62. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2004. A 52-year-old woman with postmenopausal bleeding and a cystic ovarian mass
    Richard T Penson
    Cancer Center, Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, USA
    N Engl J Med 351:2531-8. 2004
  63. ncbi request reprint Cone damage in patients receiving high-dose irofulven treatment
    Michael S Lee
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44124, USA
    Arch Ophthalmol 123:29-34. 2005
    ..To describe the clinical, perimetric, and electroretinographic (ERG) results of 4 patients with cone dysfunction following irofulven treatment including the histopathologic and immunocytochemical features of one patient's retinas...
  64. ncbi request reprint Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy
    Mory Nouriani
    Division of Gynecologic Oncology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Clin Cancer Res 10:2681-6. 2004
    ..We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma...